drugset
Drugs / Iparomlimab and Tuvonralimab
last change Feb 2026 re-read 3 minutes ago

Iparomlimab and Tuvonralimab

also known as QL1706

Monoclonal antibody

Developed for
rectal cancer
Investigated by
Hebei Medical University Fourth Hospital · Peking Union Medical College Hospital · Peking University Cancer Hospital & Institute · Shanxi Province Cancer Hospital · West China Hospital

Trials 1

today NCT07383285 · Ph 2
20262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07383285 Feb 2026 → Dec 2029 expected rectal cancer Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Iparomlimab and Tuvonralimab ClinicalTrials.gov intervention name — accepted as the source's own label NCT07383285 ↗
Known as QL1706 “QL1706” NCT07383285 ↗
Modality Monoclonal antibody “PD-1/CTLA-4 Antibody” NCT07383285 ↗